GW Pharmaceutical Archives

Debra BorchardtJune 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 billion. That has been increased as of June 17, 2021, to a range of $3.0 […]

StaffMay 5, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) closed on its acquisition of GW Pharmaceuticals and announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021. On February 3, 2021, the company said it planned to buy GW Pharmaceuticals for $220.00 per American Depositary Share for a total value of approximately $7.2 billion, or $6.7 billion net […]

Debra BorchardtApril 6, 2020

The U.S. Drug Enforcement Administration (DEA) confirmed that the GW Pharmaceuticals plc (Nasdaq: GWPH) cannabidiol drug Epidiolex is no longer subject to the Controlled Substances Act (CSA). The DEA’s letter means that all federal controlled-substance restrictions have been removed for Epidiolex. This change takes effect immediately. The stock was rising over 3% to lately trade […]

Debra BorchardtFebruary 25, 2020

GW Pharmaceuticals plc (GWPH) announced financial results for the fourth quarter and full-year ended December 31, 2019, with total net product sales of Epidiolex of $104.5 million for the fourth quarter and $296.4 million for the full year. Total revenues were $109 million and the S&P Capital IQ estimate was for revenue of $80 million […]

Debra BorchardtFebruary 3, 2020

GW Pharmaceuticals GW Pharmaceuticals (NASDAQ:GWPH) has filed a supplemental marketing application in the U.S. seeking approval to use Epidiolex (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex, a rare inherited disorder characterized by the growth on non-cancerous tumors in many parts of the body. It affects approximately 40-80 thousand individuals in the U.S. […]

Debra BorchardtNovember 5, 2019

Cannabis biotech company GW Pharmaceuticals plc (NASDAQ: GWPH) saw its share tumble in aftermarket trading despite delivering solid earnings. The company reported third-quarter net sales of $86 million and $188 million in net sales in the first three quarters of 2019. So far over 15,000 patients have received Epidiolex prescriptions since launch. The stock was […]

StaffFebruary 26, 2019

It’s time for your Daily Hit of cannabis financial news for February 26, 2019. On The Site GW Pharmaceutical GW Pharmaceuticals plc (NASDAQ: GWPH) announced its financial results for the quarter ending December 31, 2018 reflecting the company’s first sales of its cannabis drug Epidiolex. The stock jumped almost 8% in after-hours trading as the […]

Debra BorchardtFebruary 26, 2019

GW Pharmaceuticals plc (NASDAQ: GWPH) announced its financial results for the quarter ending December 31, 2018 reflecting the company’s first sales of its cannabis drug Epidiolex. The stock jumped almost 8% in after-hours trading as the biotech company beat analyst estimates. Epidiolex Sales Epidiolex is the first plant-derived cannabinoid pharmaceutical ever approved by FDA and […]

Debra BorchardtNovember 26, 2018

Before Tilray (TLRY) and Canopy Growth (CGC) took over cannabis stock portfolios, GW Pharmaceuticals plc (Nasdaq: GWPH) was the darling of the group. However, the recent positive news from this cannabis biotech company’s epilepsy study serves to remind investors that great good comes from cannabis research. On Monday, GW Pharma announced positive top-line results of the second […]

Debra BorchardtSeptember 27, 2018

The Acting Administrator of the Drug Enforcement Administration has placed FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols (THC) in schedule V. GW Pharmaceutical’s (GWPH) Epidiolex had been a schedule I controlled substance, with this new directive Epidiolex (and any generic versions of the same formulation that might be […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: GW Pharmaceutical

Jazz Pharmaceuticals Increases Guidance Based On GW Pharma Acquisition

Jazz Closes On GW Pharma, Reports Results

FDA Declares Cannabis Drug Epidiolex No Longer A Controlled Substance

GW Pharma Stock Slides Despite Strong Epidiolex Sales

Pharma Updates: GW Pharmaceutical, Zynerba

GW Pharmaceuticals Stock Tumbles After Close Despite Solid Earnings

The Daily Hit: February 26, 2019

GW Pharmaceuticals Reports First Epidiolex Sales In Earnings, Stock Jumps

GW Pharmaceuticals Stock Pops On Positive Study Results

DEA Classifies GW Pharmaceutical’s Epidiolex As A Schedule 5 Drug

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox

Get the latest cannabis news delivered right to your inbox